Register for our free email digests:
Manufacturing
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
German Funds Deny Tenders Link To Shortages
Leaked political proposals to stop German insurance funds awarding tender contracts to just one supplier would not help to prevent drug shortages, insists the leading AOK group of funds.
India's USV Reveals Investment Plans
Indian firm USV plans to spend $56.4m on a new drug formulations unit in Vadodara and $11.3m to upgrade its existing API unit near Mumbai as it eyes expanded capacity and additional sales in Europe.
The Factory Floor: Suanfarma Expands API Capacity With Sandoz Deal In Italy
Suanfarma acquires an API manufacturing facility in Italy to accelerate its growth in Europe, while CapsCanada relocates its headquarters as part of its growth strategy. Meanwhile, Glenmark, Aurobindo and Cipla struggle with quality issues.
Nitrosamine Issue Presages Paradigm Shift In Quality
The detection of cancer-causing impurities in drugs with well-established safety profiles may force regulators across the globe to revise their approach for evaluating quality.
Mylan Will Invest $1bn In India
Generics giant Mylan, which has a large chunk of its manufacturing operations in India, has said it will invest $1bn over the next five to six years in the country, maintaining the spending pace the company has established over the last few years.
Teligent Weighs Sales Of Non-Core Assets
US topicals, ophthalmics and injectables generics player Teligent has asked an investment bank to help it explore selling off non-core assets. The New Jersey-based firm wants funds to help capitalize on its newly built injectables facility.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.